Key Takeaways GKOS posted 25% YoY revenue growth in Q1 2025 to $106.7M, led by$21M in iDose TR sales. GKOS is advancing a rich pipeline, including Epioxa and PRESERFLO, to fuel long-term growth. GKOS expects mid-single-digit 2025 declines in non-iDose revenues due to LCD and legacy MIGS pressure.Glaukos Corporation (GKOS) continues to reshape the ophthalmology landscape, backed by a record-breaking first-quarter 2025 performance. The company posted revenues of $106.7 million, reflecting a 25% year-over-y ...